Blocking PD-L1 for anti-liver cancer immunity: USP22 represents a critical cotarget.

Blocking PD-L1 for anti-liver cancer immunity: USP22 represents a critical cotarget. Cell Mol Immunol. 2019 Dec 19;: Authors: Huang X, Zhang X, Bai X, Liang T PMID: 31857703 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31857703?dopt=Abstract

Source: Cellular and Molecular Immunology - December 18, 2019 Category: Molecular Biology Authors: Huang X, Zhang X, Bai X, Liang T Tags: Cell Mol Immunol Source Type: research